刊名:Urologic Oncology: Seminars and Original Investigations
出版年:2017
出版时间:January 2017
年:2017
卷:35
期:1
页码:14-20
全文大小:407 K
卷排序:35
文摘
PD-1/PD-L1 pathway may be manipulated by cancer cells to subvert the immune system. Anti-PD-L1 antibody atezolizumab is approved for metastatic urothelial carcinoma. Immunohistochemistry limits the use of PD-L1 as a prognostic biomarker.